Inventiva S.A. (NASDAQ:IVA) Short Interest Update

Inventiva S.A. (NASDAQ:IVA) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, a growth of 34.9% from the March 31st total of 57,600 shares. Based on an average trading volume of 39,500 shares, the days-to-cover ratio is currently 2.0 days.

Analyst Ratings Changes

Several brokerages have recently weighed in on IVA. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Inventiva in a report on Monday, April 1st. Stifel Nicolaus lowered their price objective on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Canaccord Genuity Group increased their target price on shares of Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Finally, Lifesci Capital restated an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $17.00.

Institutional Trading of Inventiva

An institutional investor recently raised its position in Inventiva stock. Commonwealth Equity Services LLC increased its holdings in Inventiva S.A. (NASDAQ:IVA) by 20.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,435 shares of the company’s stock after acquiring an additional 4,155 shares during the period. Commonwealth Equity Services LLC’s holdings in Inventiva were worth $103,000 at the end of the most recent reporting period. 19.06% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Stock Up 2.8 %

IVA stock opened at $3.25 on Friday. Inventiva has a one year low of $2.40 and a one year high of $5.05. The firm has a 50-day moving average of $3.63 and a two-hundred day moving average of $3.90.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.